Skip to main content

Advertisement

SpringerLink
Log in

Downregulation of miR-329 promotes cell invasion by regulating BRD4 and predicts poor prognosis in hepatocellular carcinoma

  • Original Article
  • Published:
Tumor Biology

Abstract

Increasing evidence indicates that abnormal microRNA (miRNA) expression is related to hepatocellular carcinoma (HCC) development. Our study aimed to elucidate the essential role of miR-329 in HCC progression. Real-time PCR was used to analyze miR-329 and bromodomain containing 4 (BRD4) expression in HCC samples (n = 135). Cell Counting Kit-8 (CCK-8) and flow cytometric analysis were used to investigate cell proliferation and apoptosis. The transwell assay was used to examine the cell invasive ability. The regulation mechanism was confirmed by luciferase reporter and western blot assays. Kaplan-Meier analysis was used to detect the function of miR-329 on the prognosis of HCC patients. miR-329 was decreased in HCC samples and was related to tumor development. Furthermore, miR-329 significantly regulated cell invasion by targeting BRD4 but had no effect on cell proliferation and apoptosis. Moreover, downregulation of miR-329 predicted poor prognosis of HCC patients. miR-329 could control cell invasion via regulating BRD4 expression and may be a prognostic marker in HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Abbreviations

BRD4:

Bromodomain containing 4

HCC:

Hepatocellular carcinoma

UTR:

Untranslated region

siRNA:

Small interfering RNA

CCK-8:

Cell Counting Kit-8

References

  1. Esquela-Kerscher A, Slack FJ. Oncomirs—micrornas with a role in cancer. Nat Rev Cancer. 2006;6:259–69.

    Article  CAS  PubMed  Google Scholar 

  2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.

    Article  CAS  PubMed  Google Scholar 

  3. Yang XW, Shen GZ, Cao LQ, Jiang XF, Peng HP, Shen G, et al. Microrna-1269 promotes proliferation in human hepatocellular carcinoma via downregulation of foxo1. BMC Cancer. 2014;14:909.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Zhou J, Lu S, Yang S, Chen H, Shi H, Miao M, et al. Microrna-127 post-transcriptionally downregulates sept7 and suppresses cell growth in hepatocellular carcinoma cells. Cell Physiol Biochem. 2014;33:1537–46.

    Article  CAS  PubMed  Google Scholar 

  5. Li H, Li Y, Liu D, Sun H, Liu J. Mir-224 is critical for celastrol-induced inhibition of migration and invasion of hepatocellular carcinoma cells. Cell Physiol Biochem. 2013;32:448–58.

    Article  CAS  PubMed  Google Scholar 

  6. Bartel DP. Micrornas: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.

    Article  CAS  PubMed  Google Scholar 

  7. Xiao B, Tan L, He B, Liu Z, Xu R. Mirna-329 targeting e2f1 inhibits cell proliferation in glioma cells. J Transl Med. 2013;11:172.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Yang H, Li Q, Zhao W, Yuan D, Zhao H, Zhou Y. Mir-329 suppresses the growth and motility of neuroblastoma by targeting kdm1a. FEBS Lett. 2014;588:192–7.

    Article  CAS  PubMed  Google Scholar 

  9. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.

    Article  CAS  PubMed  Google Scholar 

  10. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis b virus and hepatitis c virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529–38.

    Article  PubMed  Google Scholar 

  11. Prete SD, Montella L, Caraglia M, Maiorino L, Cennamo G, Montesarchio V, et al. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: Multicenter phase II so.LAR. study. Cancer Chemother Pharmacol. 2010;66:837–44.

    Article  CAS  PubMed  Google Scholar 

  12. Montella L, Addeo R, Caraglia M, Faiola V, Guarrasi R, Vincenzi B, et al. Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency ablation plus octreotide: a single center experience. Oncol Rep. 2008;20:385–90.

    CAS  PubMed  Google Scholar 

  13. Colombino M, Sperlongano P, Izzo F, Tatangelo F, Botti G, Lombardi A, et al. Braf and pik3ca genes are somatically mutated in hepatocellular carcinoma among patients from south Italy. Cell Death Dis. 2012;3:e259.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Wang YH, Sui YN, Yan K, Wang LS, Wang F, Zhou JH. Brd4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance. Oncol Rep. 2015;33:1699–706.

    PubMed  Google Scholar 

  15. Hu Y, Zhou J, Ye F, Xiong H, Peng L, Zheng Z, et al. Brd4 inhibitor inhibits colorectal cancer growth and metastasis. Int J Mol Sci. 2015;16:1928–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Zhang P, Dong Z, Cai J, Zhang C, Shen Z, Ke A, et al. Brd4 promotes tumor growth and epithelial-mesenchymal transition in hepatocellular carcinoma. Int J Immunopathol Pharmacol. 2015;28:36–44.

    Article  CAS  PubMed  Google Scholar 

  17. Huang D, Du X, Yuan R, Chen L, Liu T, Wen C, et al. Rock2 promotes the invasion and metastasis of hepatocellular carcinoma by modifying mmp2 ubiquitination and degradation. Biochem Biophys Res Commun. 2014;453:49–56.

    Article  CAS  PubMed  Google Scholar 

  18. Stiuso P, Potenza N, Lombardi A, Ferrandino I, Monaco A, Zappavigna S, et al. Microrna-423-5p promotes autophagy in cancer cells and is increased in serum from hepatocarcinoma patients treated with sorafenib. Mol Ther Nucleic Acids. 2015;4:e233.

    Article  CAS  PubMed  Google Scholar 

  19. Vaira V, Roncalli M, Carnaghi C, Faversani A, Maggioni M, Augello C, et al. Microrna-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma. Liver Int. 2015;35:1077–86.

    Article  CAS  PubMed  Google Scholar 

  20. Shi L, Zhang S, Wu H, Zhang L, Dai X, Hu J, et al. Mir-200c increases the radiosensitivity of non-small-cell lung cancer cell line a549 by targeting vegf-vegfr2 pathway. PLoS One. 2013;8, e78344.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Lewis H, Lance R, Troyer D, Beydoun H, Hadley M, Orians J, et al. Mir-888 is an expressed prostatic secretions-derived microrna that promotes prostate cell growth and migration. Cell Cycle. 2013;13.

  22. Kim J, Wu L, Zhao JC, Jin HJ, Yu J. Tmprss2-erg gene fusions induce prostate tumorigenesis by modulating microrna mir-200c. Oncogene. 2013.

  23. Akanuma N, Hoshino I, Akutsu Y, Murakami K, Isozaki Y, Maruyama T, et al. Microrna-133a regulates the mrnas of two invadopodia-related proteins, fscn1 and mmp14, in esophageal cancer. Br J Cancer. 2013.

  24. Yu X, Li H, Jiang X, Guo L, Jiang W, Lu SH. Mir-203 inhibits the proliferation and self-renewal of esophageal cancer stem-like cells by suppressing stem renewal factor bmi-1. Stem Cells Dev. 2013.

  25. Li Z, Yu X, Wang Y, Shen J, Wu WK, Liang J, et al. By downregulating tiam1 expression, microrna-329 suppresses gastric cancer invasion and growth. Oncotarget. 2014.

Download references

Acknowledgments

Thanks to Dr. Junwei Tang (The First Affiliated Hospital of Nanjing Medical University, Nanjing, China) for providing the HCC samples and cell lines.

Compliance with ethical standards

ᅟ

Conflicts of interest

None

Ethics approval and consent to participate

The informed consent approval from The First Affiliated Hospital of Nanjing Medical University Institute Research Ethics Committee was obtained.

Author information

Author notes

    Authors and Affiliations

    1. Department of Gastrointestinal Surgery, Affiliated Yixing Hospital of Jiangsu University, Yixing, 214200, China

      Jianping Zhou

    2. Department of Obstetrics and Gynecology, Affiliated Yixing Hospital of Jiangsu University, Yixing, 214200, China

      Weiling Li

    3. Department of B-Ultrasound Room, Affiliated Yixing Hospital of Jiangsu University, Yixing, 214200, China

      Jianfeng Guo & Gang Li

    4. Department of Operating Theater, Affiliated Yixing Hospital of Jiangsu University, Yixing, 214200, China

      Fang Chen

    5. Department of Orthopedic, Affiliated Yixing Hospital of Jiangsu University, Yixing, 214200, China

      Jiangang Zhou

    Authors
    1. Jianping Zhou
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Weiling Li
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Jianfeng Guo
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Gang Li
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Fang Chen
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Jiangang Zhou
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Jiangang Zhou.

    Additional information

    Jianping Zhou and Weiling Li contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Zhou, J., Li, W., Guo, J. et al. Downregulation of miR-329 promotes cell invasion by regulating BRD4 and predicts poor prognosis in hepatocellular carcinoma. Tumor Biol. 37, 3561–3569 (2016). https://doi.org/10.1007/s13277-015-4109-4

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s13277-015-4109-4

    Keywords

    Search

    Navigation